561 related articles for article (PubMed ID: 28035003)
21. Anti-angiogenic treatment (Bevacizumab) improves the responsiveness of photodynamic therapy in colorectal cancer.
Peng CL; Lin HC; Chiang WL; Shih YH; Chiang PF; Luo TY; Cheng CC; Shieh MJ
Photodiagnosis Photodyn Ther; 2018 Sep; 23():111-118. PubMed ID: 29894822
[TBL] [Abstract][Full Text] [Related]
22. Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation.
Brossa A; Grange C; Mancuso L; Annaratone L; Satolli MA; Mazzone M; Camussi G; Bussolati B
Oncotarget; 2015 May; 6(13):11295-309. PubMed ID: 25948774
[TBL] [Abstract][Full Text] [Related]
23. VEGF-Independent Angiogenic Factors: Beyond VEGF/VEGFR2 Signaling.
Eguchi R; Kawabe JI; Wakabayashi I
J Vasc Res; 2022; 59(2):78-89. PubMed ID: 35152220
[TBL] [Abstract][Full Text] [Related]
24. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.
Zhou X; Yue GG; Liu M; Zuo Z; Lee JK; Li M; Tsui SK; Fung KP; Sun H; Pu J; Lau CB
Oncotarget; 2016 Dec; 7(50):82820-82835. PubMed ID: 27756875
[TBL] [Abstract][Full Text] [Related]
25. Phostine 3.1a as a pharmacological compound with antiangiogenic properties against diseases with excess vascularization.
Bousseau S; Marchand M; Soleti R; Vergori L; Hilairet G; Recoquillon S; Le Mao M; Gueguen N; Khiati S; Clarion L; Bakalara N; Martinez MC; Germain S; Lenaers G; Andriantsitohaina R
FASEB J; 2019 May; 33(5):5864-5875. PubMed ID: 30817178
[TBL] [Abstract][Full Text] [Related]
26. Effect of YangZheng XiaoJi Extract, DME-25, on Endothelial Cells and their Response to Avastin.
Owen S; Gao Y; Zhi X; Wei C; Wu Y; Jiang WG
Anticancer Res; 2016 Mar; 36(3):1181-92. PubMed ID: 26977014
[TBL] [Abstract][Full Text] [Related]
27. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor.
Mésange P; Poindessous V; Sabbah M; Escargueil AE; de Gramont A; Larsen AK
Oncotarget; 2014 Jul; 5(13):4709-21. PubMed ID: 25015210
[TBL] [Abstract][Full Text] [Related]
28. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.
Lucio-Eterovic AK; Piao Y; de Groot JF
Clin Cancer Res; 2009 Jul; 15(14):4589-99. PubMed ID: 19567589
[TBL] [Abstract][Full Text] [Related]
29. Vascular Endothelial Growth Factor Blockade Induces Dermal Endothelial Cell Apoptosis in a Clinically Relevant Skin Organ Culture Model.
Luengas-Martinez A; Hardman-Smart J; Rutkowski D; Purba TS; Paus R; Young HS
Skin Pharmacol Physiol; 2020; 33(3):110-118. PubMed ID: 32570235
[TBL] [Abstract][Full Text] [Related]
30. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
[TBL] [Abstract][Full Text] [Related]
31. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
32. Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.
Fan Y; Peng A; He S; Shao X; Nie C; Chen L
J Chemother; 2013 Oct; 25(5):298-308. PubMed ID: 24070138
[TBL] [Abstract][Full Text] [Related]
33. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
34. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
[TBL] [Abstract][Full Text] [Related]
35. How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy.
Blagosklonny MV
Cancer Biol Ther; 2005 Dec; 4(12):1307-10. PubMed ID: 16322683
[TBL] [Abstract][Full Text] [Related]
36. Total saponins from Albizia julibrissin inhibit vascular endothelial growth factor-mediated angiogenesis in vitro and in vivo.
Cai W; Li Y; Yi Q; Xie F; Du B; Feng L; Qiu L
Mol Med Rep; 2015 May; 11(5):3405-13. PubMed ID: 25607254
[TBL] [Abstract][Full Text] [Related]
37. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
38. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
Jain RK
Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
[TBL] [Abstract][Full Text] [Related]
39. Anti-angiogenic effect of furanodiene on HUVECs in vitro and on zebrafish in vivo.
Zhong ZF; Hoi PM; Wu GS; Xu ZT; Tan W; Chen XP; Cui L; Wu T; Wang YT
J Ethnopharmacol; 2012 Jun; 141(2):721-7. PubMed ID: 21911050
[TBL] [Abstract][Full Text] [Related]
40. Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies.
Guyot M; Hilmi C; Ambrosetti D; Merlano M; Lo Nigro C; Durivault J; Grépin R; Pagès G
Oncotarget; 2017 Feb; 8(6):9174-9188. PubMed ID: 27999187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
